Brainstorm Cell Therapeutics Statistics
Share Statistics
Brainstorm Cell Therapeutics has 7.25M
shares outstanding. The number of shares has increased by 21.47%
in one year.
| Shares Outstanding | 7.25M |
| Shares Change (YoY) | 21.47% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 4.81% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 74,247 |
| FTD / Avg. Volume | 42.72% |
Short Selling Information
The latest short interest is 291.42K, so 5.11% of the outstanding
shares have been sold short.
| Short Interest | 291.42K |
| Short % of Shares Out | 5.11% |
| Short % of Float | 5.39% |
| Short Ratio (days to cover) | 1.85 |
Valuation Ratios
The PE ratio is 1.04 and the forward
PE ratio is -1.
Brainstorm Cell Therapeutics's PEG ratio is
0.
| PE Ratio | 1.04 |
| Forward PE | -1 |
| PS Ratio | 14.2 |
| Forward PS | 0.3 |
| PB Ratio | -1.55 |
| P/FCF Ratio | -1.33 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Brainstorm Cell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04,
with a Debt / Equity ratio of -0.09.
| Current Ratio | 0.04 |
| Quick Ratio | 0.04 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $31,444.44 |
| Profits Per Employee | $430,481.48 |
| Employee Count | 27 |
| Asset Turnover | 0.46 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.01% in the
last 52 weeks. The beta is 0.34, so Brainstorm Cell Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.34 |
| 52-Week Price Change | -85.01% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 50.15 |
| Average Volume (20 Days) | 173,786 |
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 849K
and earned 11.62M
in profits. Earnings per share was 2.19.
| Revenue | 849K |
| Gross Profit | 849K |
| Operating Income | n/a |
| Net Income | 11.62M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | 2.19 |
Full Income StatementBalance Sheet
The company has 187K in cash and 720K in
debt, giving a net cash position of -533K.
| Cash & Cash Equivalents | 187K |
| Total Debt | 720K |
| Net Cash | -533K |
| Retained Earnings | -226.64M |
| Total Assets | 1.83M |
| Working Capital | -8.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.09M
and capital expenditures 0, giving a free cash flow of -9.09M.
| Operating Cash Flow | -9.09M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.09M |
| FCF Per Share | -1.71 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of 0% and 1369.02%.
| Gross Margin | 100% |
| Operating Margin | n/a |
| Pretax Margin | 1369.02% |
| Profit Margin | 1369.02% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1071.02% |
